Biomarkers /
RAD51B
Overview
RAD51B is altered in 0.42% of all cancers with lung adenocarcinoma, cutaneous melanoma, bladder urothelial carcinoma, endometrial endometrioid adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in RAD51B are RAD51B Mutation (0.32%), RAD51B Loss (0.15%), RAD51B Amplification (0.05%), RAD51B Fusion (0.01%), and RAD51B P109S (0.01%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of RAD51B in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.